Form 4: Eledon Pharmaceuticals Director June Lee Acquires Stock Options and Restricted Stock Units
SEC Form 4 Filing
Eledon Pharmaceuticals director June Lee was granted stock options for 30,870 shares and 3,430 restricted stock units on January 10, 2025.
Summary
- Director June Lee of Eledon Pharmaceuticals acquired stock options for 30,870 shares at an exercise price of $4.04 per share on January 10, 2025.
- These options vest 100% on January 10, 2026.
- Additionally, Lee received 3,430 restricted stock units (RSUs), each representing one share of common stock, also vesting 100% on January 10, 2026.
- The reporting person now beneficially owns these options and RSUs.
Sentiment
Score: 7
Explanation: The document reflects a routine grant of equity compensation, which is generally viewed positively as it aligns director interests with shareholders. There are no negative implications.
Positives
- The grant of stock options and RSUs to a director aligns their interests with the company's long-term success.
- The vesting schedule encourages long-term commitment from the director.
Industry Context
This is a standard practice for incentivizing directors and aligning their interests with shareholders in the pharmaceutical industry.
Comparison to Industry Standards
- Stock options and restricted stock units are common forms of equity compensation for directors in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
- Vesting schedules, such as the one-year cliff vesting in this case, are also typical to ensure long-term commitment.
- The specific number of shares and exercise price would be determined by the company's compensation policy and the director's role and responsibilities.
Stakeholder Impact
- Shareholders may view this positively as it aligns the director's interests with the company's performance.
- Employees may see this as a sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/10/2025 | Date of transaction for stock options and restricted stock units. |
| 01/10/2026 | Vesting date for both stock options and restricted stock units. |
| 01/10/2035 | Expiration date for the stock options. |
| 01/13/2025 | Date of filing of the form. |
Keywords
Eledon Pharmaceuticals, stock options, restricted stock units, director, insider trading, equity compensation, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.